Media Articles Related to Zolinza (Vorinostat)
First PD Inhibitor in Hematology: Nivolumab for Lymphoma
Source: Medscape Hematology-Oncology Headlines [2016.05.18]
The latest indication to be approved for the programmed cell death (PD) inhibitor nivolumab (Opdivo) is relapsed Hodgkin's lymphoma.
Glasgow study could boost effectiveness of chemotherapy in the treatment of lymphoma
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2016.05.11]
A study by scientists at the University of Glasgow, which reveals the critical role a common cancer-associated gene plays in lymphoma development, could lead to improved treatments for a range of...
Combination therapy incorporating 3 new agents shows promise as treatment for aggressive lymphoma
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2016.04.20]
New research from Roswell Park Cancer Institute (RPCI) shows that promising cancer drugs used in combination can have significant therapeutic impact on a particularly aggressive subtype of diffuse...
Lymphoma overrides a key protein's quadruple locks
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2016.03.22]
Protein chemists at Johns Hopkins report they are closer to explaining why certain blood cancers are able to crack a molecular security system and run rampant.
Young Black, Hispanic Hodgkin Lymphoma Patients Face Worse Outcomes: Study
Source: MedicineNet Non-Hodgkins Lymphomas Specialty [2016.02.04]
Title: Young Black, Hispanic Hodgkin Lymphoma Patients Face Worse Outcomes: Study
Category: Health News
Created: 2/3/2016 12:00:00 AM
Last Editorial Review: 2/4/2016 12:00:00 AM
Published Studies Related to Zolinza (Vorinostat)
A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. [2010.07]
Histone deacetylase inhibitors (HDACi) affect chromatin remodelling and modulate the expression of aberrantly silenced genes. HDACi have single-agent clinical activity in haematological malignancies and have synergistic anti-leukaemia activity when combined with anthracyclines in vitro... The combination of vorinostat and idarubicin is generally tolerable and active in patients with advanced leukaemia and should be studied in the front-line setting.
Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. [2010.01.01]
PURPOSE Vorinostat, a histone deacetylase inhibitor, exerts anticancer effects by both histone and nonhistone-mediated mechanisms...
Carboplatin and Paclitaxel in combination with either vorinostat or placebo for
first-line therapy of advanced non-small-cell lung cancer. 
PURPOSE Vorinostat, a histone deacetylase inhibitor, exerts anticancer effects by
both histone and nonhistone-mediated mechanisms...
A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancer. [2009.11.15]
CONCLUSIONS: Administration of a single supratherapeutic dose of the histone deacetylase inhibitor vorinostat is not associated with prolongation of the QTc interval. A dedicated QTc study in advanced cancer patients is a robust means for assessing risk for ventricular repolarization prolongation.
Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. [2011.11.12]
Purpose Combining proteasome and histone deacetylase (HDAC) inhibition has been seen to provide synergistic anti-tumor activity, with complementary effects on a number of signaling pathways. The novel bi-cyclic structure of marizomib with its unique proteasome inhibition, toxicology and efficacy profiles, suggested utility in combining it with an HDAC inhibitor such as vorinostat...
Clinical Trials Related to Zolinza (Vorinostat)
Vorinostat Plus FND in Relapsed or Refractory Mantle Cell Lymphoma [Not yet recruiting]
1. Rationale In mantle cell lymphoma, the conventional chemotherapy achieves only
temporary responses with a median duration of remissions only from 1 to 2 years.
Therefore, mantle cell lymphoma is known as one of the B-cell lymphomas with poor
prognosis. Although the treatment outcome of mantle cell lymphoma has been improved
since intensive chemotherapy regimens such as HyperCVAD was used, a substantial number
of patients are still frequently relapsed after chemotherapy. After relapse, most of
them became refractory to various kinds of salvage treatment. That is why the results
of most salvage chemotherapy regimens were disappointing. In addition, mantle cell
lymphoma generally occurs in elderly people. Thus, intensive salvage chemotherapy may
not be feasible for elderly patients. Therefore, an effective, novel combination
treatment is urgently needed in relapsed or refractory mantle cell lymphoma patients.
- Vorinostat will produce synergism with a combination treatment regimen
(Fludarabine, mitoxantrone, dexamethasone, FND) without overlapping toxicity
- Vorinostat maintenance treatment will reduce the relapse rate in patients
ineligible for autologous stem cell transplantation.
3. Purpose A phase II investigation to determin the effectiveness of vorinostat in
combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients
with relapsed or refractory mantle cell lymphomain patients with relapsed or refractory
mantle cell lymphoma.
Study of Suberoylanilide Hydroxamic Acid (SAHA) With Temsirolimus in Children With Diffuse Intrinsic Pontine Glioma (DIPG) [Not yet recruiting]
The goal of this clinical research study is to learn the highest tolerable dose of
temsirolimus that can be combined with a stable dose of vorinostat and/or radiation therapy
and given to patients with DIPG. The safety of this treatment combination will also be
Study of Vorinostat Plus Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer [Active, not recruiting]
There is scientific rationale for exploring the role of vorinostat, histone deacetylase
inhibitor with capecitabine (X) and cisplatin (P), one of standard chemotherapy in patients
with advanced gastric cancer. XP is a new standard of care in advanced gastric cancer (AGC)
and vorinostat is a novel targeted agent that prevents tumor cell proliferation, survival
and angiogenesis through histone deacetylase inhibition.
Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1)) [Completed]
The purposes of this study are:
- To determine the maximum tolerated dose (MTD) for the combination of oral vorinostat
and bortezomib in participants with advanced multiple myeloma
- To assess the safety and tolerability of this regimen and to document the participant's
clinical status (by anti-tumor activity) for this combination, as determined per
standard of care.
MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies [Recruiting]
The goal of this clinical research study is to find the highest tolerable dose of the
combination of MLN9708 and vorinostat that can be given to patients with advanced solid
tumors. The safety of these drugs will also be studied.
Reports of Suspected Zolinza (Vorinostat) Side Effects
Decreased Appetite (12),
Pleural Effusion (8),
Febrile Neutropenia (8),
Disease Progression (6),
White Blood Cell Count Decreased (6),
Renal Failure (6), more >>